Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Five things to know for your Memorial Day great escape
Expect crowds at airports and on the highways as holiday travel surges over Memorial Day weekend,... -
New Arlington Heights mayor taps election opponent as his second-in-command
New Arlington Heights Mayor Jim Tinaglia choose his former election opponent Tom Schwingbeck as president pro... -
One person dead following head-on collision in Elgin Monday
One person died after a head-on collision on Randall Road in Elgin Monday afternoon.